Nasopharyngeal cancer. ESMO 2024 news

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Nasopharyngeal cancer (NPC) belongs to the group of orphan malignant neoplasms. This nosology is characterized by a modest arsenal of treatment options for both localized and widespread forms. The above facts explain the extremely unsatisfactory results of treatment of patients with nasopharyngeal carcinoma. Major recent international conferences have not presented breakthrough studies in this area beyond the Chinese protocols using chemo-immunotherapy for recurrent/metastatic forms of the disease. The exception was the latest congress of the European Society of Medical Oncology (ESMO), which was held from September 13 to 17 in Barcelona, Spain. In this review article, we discuss the most significant studies on the treatment of patients with nasopharyngeal carcinoma that were reported at ESMO 2024 and may change the routine practice of an oncologist in the near future.

Texto integral

Acesso é fechado

Sobre autores

Pavel Golubev

Moscow City Hospital n.a. S.S. Yudin of the Moscow Healthcare Department

Autor responsável pela correspondência
Email: golubev194@gmail.com
ORCID ID: 0000-0003-3532-6476
Código SPIN: 9592-7730

Cand. Sci. (Med.), Oncologist, Chemotherapy Department No. 2 of the Oncology Center No. 1

Rússia, Moscow

L. Bolotina

National Medical Research Center of Radiology

Email: golubev194@gmail.com
ORCID ID: 0000-0003-4879-2687
Código SPIN: 2787-5414

P. Hertsen Moscow Oncological Research Institute

Rússia, Moscow

E. Kuzmina

Moscow City Hospital n.a. S.S. Yudin of the Moscow Healthcare Department

Email: golubev194@gmail.com
ORCID ID: 0009-0007-2856-5176
Rússia, Moscow

I. Pokataev

Moscow City Hospital n.a. S.S. Yudin of the Moscow Healthcare Department

Email: golubev194@gmail.com
ORCID ID: 0000-0001-9864-3837
Rússia, Moscow

A. Golubeva

Samara State Medical University

Email: golubev194@gmail.com
ORCID ID: 0009-0003-8634-4487
Rússia, Samara

E. Kyanzhin

Samara State Medical University

Email: golubev194@gmail.com
ORCID ID: 0009-0001-7013-9468
Rússia, Samara

V. Kuzmin

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: golubev194@gmail.com
ORCID ID: 0009-0000-9658-3586
Rússia, Moscow

V. Galkin

Moscow City Hospital n.a. S.S. Yudin of the Moscow Healthcare Department

Email: golubev194@gmail.com
ORCID ID: 0000-0002-6619-6179
Rússia, Moscow

Bibliografia

  1. Каприн А.Д. и др. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). М., 2024. 276 с. илл. [Kaprin A.D., et al. Malignant neoplasms in Russia in 2023 (morbidity and mortality). M., 2024. 276 p. (In Russ.)].
  2. Global Cancer Obserbvatory. Cancer Today. URL: http://gco.iarc.fr.
  3. Бычков Ю.М., Мудунов А.М., Гельфанд И.М. и др. Клинический случай успешного применения ниволумаба в лечении рецидивного диссеминированного рака носоглотки. Опухоли головы и шеи. 2019;9(2):99–doi: 10.17650/2222-1468-2019-9-2-99-104. [Bychkov Yu.M., Mudunov A.M., Gelfand I.M., et al. Successful treatment of recurrent metastatic nasopharyngeal carcinoma with nivolumab: a case report. Head and Neck Tumors (HNT). 2019;9(2):99–104 (In Russ.)].
  4. Рак носоглотки. Клинические рекомендации [Электронный ресурс]. Ассоциация онкологов России. М, 2020. 43 с. [Nasopharyngeal cancer. Clinical guidelines [Electronic resource]. Association of Oncologists of Russia. M., 2020. 43 p. (In Russ.)]. URL: https://oncology-association.ru/wp-content/uploads/2020/09/rak_nosoglotki.pdf
  5. Болотина Л.В., Владимирова Л.Ю., Деньги-на Н.В. и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи. Злокачественные опухоли. 2022;12(3s2-1):94–112. doi: 10.18027/2224-5057-2022-12-3s2-94-112. [Bolotina L.V., Vladimirova L.Yu., Dengina N.V., et al. Practical recommendations for the treatment of malignant tumors of the head and neck. Malignant tumors. 2022;12(3s2-1):94–112 (In Russ.)].
  6. Мудунов А.М., Нариманов М.Н., Сафаров Д.А. Новые возможности иммунотерапии в лечении распространенного рецидивного плоскоклеточного рака органов головы и шеи. Опухоли головы и шеи. 2017;7(2):99–105. doi: 10.17650/2222-1468-2017-7-2-99-105. [Mudunov A.M., Narimanov M.N., Safarov D.A. New possibilities of immunotherapy in the treatment of widespread recurrent squamous cell carcinoma of the head and neck organs. Head and Neck Tumors (HNT). 2017;7(2):99–105 (In Russ.)].
  7. Болотина Л.В., Устинова Т.В., Дешкина Т.И. и др. Рациональная последовательность моноклональных антител в лечении нерезектабельного плоскоклеточного рака головы и шеи. Опухоли головы и шеи. 2022;12(1):35–52. doi: 10.17650/2222-1468-2022-12-1-35-52. [Bolotina L.V., Ustinova T.V., Dеshkina T.I., et al. Rational sequence of monoclonal antibodies in the treatment of non-resectable head and neck squamous cell carcinoma. Head and Neck Tumors (HNT). 2022;12(1):35–52 (In Russ.)].
  8. Yang Y., Pan J., et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061–1072.e4. doi: 10.1016/j.ccell.2023.04.014.
  9. Mai H.Q., Chen Q.Y., et al. Toripalimab Plus Chemotherapy for Recurrentor Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023;330(20):1961–1970. doi: 10.1001/jama.2023.20181.
  10. Yang Y., Qu S., et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162–74. doi: 10.1016/S1470-2045(21)00302-8.
  11. Ling Guo, Zi-Jian Lu, Qi Yang, et al. Comparing Paclitaxel plus Cisplatin versus Cisplatin in Concurrent Chemoradiotherapy for Stage IV Locoregionally Advanced Nasopharyngeal Carcinoma: A phase II Randomized Trial. URL: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/comparing-paclitaxel-plus-cisplatin-versus-cisplatin-in-concurrent-chemoradiotherapy-for-stage-iv-locoregionally-advanced-nasopharyngeal-carcinoma
  12. Min Li, Shenhong Qu, Guiping Lan, et al. Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: Aprospective, single-arm, phase II trial. URL: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/tislelizumab-combined-with-induction-chemotherapy-and-concurrent-chemoradiotherapy-for-locoregionally-advanced-nasopharyngeal-carcinoma-a-prospect.
  13. Chaosu Hu, Fen Xue, Dan Ou, et al. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial. URL: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/sequential-chemoradiotherapy-versus-induction-chemotherapy-plus-concurrent-chemoradiotherapy-for-locoregionally-advanced-nasopharyngeal-carcinoma.
  14. Wan-Qin Chong, Jia-Li Low, Kenneth Sooi, et al. Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). URL: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/phase-ii-open-label-randomized-study-of-pembrolizumab-with-or-without-bevacizumab-in-platinum-resistant-recurrent-metastatic-nasopharyngeal-carcinoma.
  15. Chan A.T.C., Lee V.H.F., Hong R.L., et al. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol. 2023;34(3):251–61. doi: 10.1016/j.annonc.2022.12.007.
  16. Gurizzan C., Farinatti S., Alberti A. et al. Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: the POINT study. URL: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/pembrolizumab-and-olaparib-in-recurrent-metastatic-platinum-resistant-nasopharyngeal-cancer-the-point-study
  17. Xi Ding，Zhengkai Feng, Youping Liu, et al. Camrelizumab Plus Dalpiciclibin Anti-PD-1 Refractory Recurrentor Metastatic Nasopharyngeal Carcinoma. URL: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/camrelizumab-plus-dalpiciclib-in-anti-pd-1-refractory-recurrent-or-metastatic-nasopharyngeal-carcinoma

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Fig. 1. A - Three-year event-free survival in all patients included in this protocol; B - Three-year event-free survival in patients who completed the entire treatment course

Baixar (167KB)
Metadados
3. Fig. 2. Median relapse-free and overall survival in the pembrolizumab (A) and pembrolizumab + bevacizumab (B) groups

Baixar (185KB)
Metadados

Declaração de direitos autorais © Bionika Media, 2024